Page 384 - Read Online
P. 384

Verkoeijen et al. J Cancer Metastasis Treat 2019;5:51  I  http://dx.doi.org/10.20517/2394-4722.2019.06                    Page 13 of 16






































               Figure 7. Diagram depicts the hypothesized signaling pathways for JNK-paxillin dependent cell migration. Engagement of EGF receptors
               by EGF triggers rapid activation of JNK, leading to the phosphorylation of paxillin on Ser 178 which might facilitate adhesion turnover thus
               promoting rapid migration. Upon EGF stimulation, JNK phophorylates also c-Jun which regulates EGFR transcription and β-catenin which
               delocalizes from the cell-cell contact breaking down the adherens junctions. Paxillin S178A mutant protein might associate with JNK
               preventing its activation and consequently affecting AP1 activity and EGFR expression. Inactive JNK as well as down-regulation of EGFR
               result in de-phosphorylation of β-catenin and formation of stabile cell-cell contact in MTLn3 cells


               DECLARATIONS
               Acknowledgments
               We would like to thank H. de Bont for assistance with live cell imaging experiments and ImagePro Plus
               analysis. We thank H. van Dam for luciferase reporter constructs.

               Authors’ contributions
               Carried out the experiments: Verkoeijen S, Ma YF, van Roosmalen W, Lalai R, van Miltenburg MHAM, Le
               Dévédec SE
               Wrote the manuscript with support from van de Water B: Verkoeijen S, Ma YF, Le Dévédec SE
               Conceived the original idea and helped supervise the project: van de Water B
               Supervised and finalized the project: Le Dévédec SE

               Availability of data and materials
               All data are made available through supplemental data. Materials are available on request.

               Financial support and sponsorship
               This work was supported by the EU FP7 Metafight project (HEALTH-F2-2007-201862), Dutch Cancer Society
               (KWF-UL2007-3860) and NWO grant (911-02-022).


               Conflicts of interest
               All authors declared that there are no conflicts of interest.
   379   380   381   382   383   384   385   386   387   388   389